Leila Malekmakan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leila Malekmakan has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Maryam Pakfetrat
Department of Internal Medicine, Shiraz Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
20 shared publications - Jamshid Roozbeh
Nephro-Urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
14 shared publications Maryam Pakfetrat
Shiraz Univ Med Sci, Nephrourol Res Ctr, Shiraz, Iran
9 shared publicationsJamshid Roozbeh
Department of Community Medicine, Shiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
8 shared publications- Sezaneh Haghpanah
Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
7 shared publications Mina Mashayekh
Department of Community Medicine, Shiraz Nephro-urology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
6 shared publications
Latest Publications
- Open Access
- 21 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 658
Therapeutic strategies for olfactory impairment in patients with chronic kidney disease: a systematic review
Olfactory impairment is often considered a minor complication of chronic kidney disease (CKD), carrying important consequences for nutrition, safety, and overall quality of life. While several therapeutic strategies have been introduced in other populations, their effectiveness in the context of CKD remains poorly understood. This systematic review aimed to evaluate current evidence on the treatment of olfactory impairment in CKD patients, including those undergoing dialysis or kidney transplantation (KT). A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. Studies were included if they assessed therapeutic interventions targeting olfactory impairment in CKD patients. Data on study design, population, olfactory assessments, interventions, and outcomes were extracted and quality-assessed using the Effective Public Health Practice Project (EPHPP) tool. Eight studies, published from 1987 to 2023, involving 469 CKD patients were included, spanning pre-dialysis, hemodialysis (HD), peritoneal dialysis (PD), and KT populations. Olfactory impairment was highly prevalent across all groups, affecting odor identification and discrimination. While KT offered the most complete recovery, dialysis had mixed effects, with limited improvement in olfactory thresholds. Among treatments, intranasal theophylline and curcumin showed partial efficacy, while olfactory training demonstrated the most consistent improvements in subjective and objective measures. Olfactory impairment in CKD is a complex complication. Among available approaches, olfactory training stands out as a promising, non-pharmacologic option. Future clinical trials are essential to validate and refine treatment strategies tailored to the distinct metabolic and neurological challenges of CKD.Incorporating routine screening and targeted mannagement of olfactory impairment into nephrology practice may enhance overall patient care, nutritional status, and quality of life. Not applicable
- 21 November 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 658
Open AccessTherapeutic strategies for olfactory impairment in patients with chronic kidney disease: a systematic review
Olfactory impairment is often considered a minor complication of chronic kidney disease (CKD), carrying important consequences for nutrition, safety, and overall quality of life. While several therapeutic strategies have been introduced in other populations, their effectiveness in the context of CKD remains poorly understood. This systematic review aimed to evaluate current evidence on the treatment of olfactory impairment in CKD patients, including those undergoing dialysis or kidney transplantation (KT). A comprehensive literature search was conducted across PubMed, Scopus, and Web of Science. Studies were included if they assessed therapeutic interventions targeting olfactory impairment in CKD patients. Data on study design, population, olfactory assessments, interventions, and outcomes were extracted and quality-assessed using the Effective Public Health Practice Project (EPHPP) tool. Eight studies, published from 1987 to 2023, involving 469 CKD patients were included, spanning pre-dialysis, hemodialysis (HD), peritoneal dialysis (PD), and KT populations. Olfactory impairment was highly prevalent across all groups, affecting odor identification and discrimination. While KT offered the most complete recovery, dialysis had mixed effects, with limited improvement in olfactory thresholds. Among treatments, intranasal theophylline and curcumin showed partial efficacy, while olfactory training demonstrated the most consistent improvements in subjective and objective measures. Olfactory impairment in CKD is a complex complication. Among available approaches, olfactory training stands out as a promising, non-pharmacologic option. Future clinical trials are essential to validate and refine treatment strategies tailored to the distinct metabolic and neurological challenges of CKD.Incorporating routine screening and targeted mannagement of olfactory impairment into nephrology practice may enhance overall patient care, nutritional status, and quality of life. Not applicable
- Open Access
- 29 October 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 1-4
Polycythemia secondary to renal dromedary hump in a young healthy woman: a case report
Renal dromedary hump is a benign anatomic variant with same echogenicity and blood flow as normal renal parenchyma in imaging modalities. In the present study, we report secondary erythrosytosis due to renal dromedary hump in a young healthy woman. A 32-year-old, previously healthy Persian woman referred to our clinic with a 2-month history of bruises. On investigations, patient had elevated hemoglobin (19 g/dL) hematocrit (69%), red blood cell count (7.5 million per microliter) and serum erythropoietin level (708 mU/mL). The only abnormal finding in imaging modalities were a renal dromedary hump in the left kidney, mild splenomegaly, and kidney enlargement. Secondary polycythemia due to renal dromedary hump was the most likely diagnosis. The patient refuses further investigations or treatment. She occasionally comes to our clinic for phlebotomy. Dromadory hump as focal bulging of left kidney may contain a group of erythropoietin-producing cells. We think that these cells may begin to produce erythropoietin under certain circumstances. Considering the significant rise in erythropoietin level in our patient and excluding other diagnoses, we think more studies are needed to identify whether renal hump can be a source of producing erythropoietin.
- 29 October 2025
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 19 (1) , 1-4
Open AccessPolycythemia secondary to renal dromedary hump in a young healthy woman: a case report
Renal dromedary hump is a benign anatomic variant with same echogenicity and blood flow as normal renal parenchyma in imaging modalities. In the present study, we report secondary erythrosytosis due to renal dromedary hump in a young healthy woman. A 32-year-old, previously healthy Persian woman referred to our clinic with a 2-month history of bruises. On investigations, patient had elevated hemoglobin (19 g/dL) hematocrit (69%), red blood cell count (7.5 million per microliter) and serum erythropoietin level (708 mU/mL). The only abnormal finding in imaging modalities were a renal dromedary hump in the left kidney, mild splenomegaly, and kidney enlargement. Secondary polycythemia due to renal dromedary hump was the most likely diagnosis. The patient refuses further investigations or treatment. She occasionally comes to our clinic for phlebotomy. Dromadory hump as focal bulging of left kidney may contain a group of erythropoietin-producing cells. We think that these cells may begin to produce erythropoietin under certain circumstances. Considering the significant rise in erythropoietin level in our patient and excluding other diagnoses, we think more studies are needed to identify whether renal hump can be a source of producing erythropoietin.
- Open Access
- 26 April 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
The Effect of Cigarette Smoking and Alcohol Consumption on Survival in Advanced Laryngeal Cancer
Background: Laryngeal cancer is the second most common respiratory tract cancer, with a relative 5-year overall survival rate varying by tumor site. Objectives: This study aimed to evaluate the survival of patients based on epidemiological factors, as well as clinical and demographic data. Methods: The study group consisted of 150 patients with advanced laryngeal cancer who underwent total laryngectomy (TL). Demographic data, symptoms, risk factors, tumor characteristics, and postoperative complications were analyzed. Results: The overall survival rates after 1, 3, and 5 years for laryngeal cancer were 99.3%, 97.0%, and 76.5%, respectively. Patients with stage 3 disease had a significantly higher five-year survival rate than those with stage 4 disease (91.0% vs. 68.4%; log-rank: 12.6, P = 0.002). The Kaplan-Meier survival curve showed that 1-year survival was worse among patients with a positive history of alcohol consumption (45.8% vs. 96.2%; log-rank: 13.8, P < 0.001). Although the effect of smoking on survival was not statistically significant due to the small number of non-smoking patients, clinically, a higher percentage of advanced laryngeal cancer patients were smokers. Conclusions: Alcohol consumption and a high tumor stage in patients with laryngeal cancer worsen the prognosis and reduce survival.
- 26 April 2025
- Published by Brieflands in International Journal of Cancer Management
- Vol. 18 (1)
Open AccessThe Effect of Cigarette Smoking and Alcohol Consumption on Survival in Advanced Laryngeal Cancer
Background: Laryngeal cancer is the second most common respiratory tract cancer, with a relative 5-year overall survival rate varying by tumor site. Objectives: This study aimed to evaluate the survival of patients based on epidemiological factors, as well as clinical and demographic data. Methods: The study group consisted of 150 patients with advanced laryngeal cancer who underwent total laryngectomy (TL). Demographic data, symptoms, risk factors, tumor characteristics, and postoperative complications were analyzed. Results: The overall survival rates after 1, 3, and 5 years for laryngeal cancer were 99.3%, 97.0%, and 76.5%, respectively. Patients with stage 3 disease had a significantly higher five-year survival rate than those with stage 4 disease (91.0% vs. 68.4%; log-rank: 12.6, P = 0.002). The Kaplan-Meier survival curve showed that 1-year survival was worse among patients with a positive history of alcohol consumption (45.8% vs. 96.2%; log-rank: 13.8, P < 0.001). Although the effect of smoking on survival was not statistically significant due to the small number of non-smoking patients, clinically, a higher percentage of advanced laryngeal cancer patients were smokers. Conclusions: Alcohol consumption and a high tumor stage in patients with laryngeal cancer worsen the prognosis and reduce survival.
- Open Access
- 21 March 2025
- Vol. 16 (2) , 289-296
Odor olfactory dysfunction in chronic kidney disease and diabetes mellitus and its association with nutritional factors
Olfactory changes connection to deteriorated quality of life in chronic kidney disease cases (CKD) and diabetes mellitus (DM). The nutritional status is altered in CKD and DM and it closely interconnected with olfactory function. We aimed to study the olfactory dysfunction in these populations. We conducted a cross-sectional research on CKD and DM cases aged 20-50 (27 healthy controls, 77 CKD patients, and 36 DM patients). We used the Iran Smell Identification Test (Iran-SIT) version of the University of Pennsylvania Smell Identification Test (UPSIT) to evaluate the olfactory function. The significant level was set as <0.05. Our 140 cases included 51.4% of men (mean age of 46.7±10.6 years). The total score of the Iran-SIT test indicated that olfactory impairment in the CKD was higher (16.2±4.2) than in the DM (18.8±2.1) and control groups (20.4±1.2) (P=0.001). It was determined that 54.5% of CKD patients and 38.9% of the DM group had olfactory dysfunction compared to 7.4% of the controls (P=0.001). Multiple regression analysis indicated that being men and low-density lipoprotein cholesterol (LDL-C) were related to olfactory dysfunction in the total population (OR: 4.55, P=0.037, and OR: 0.94, P=0.037). Still, it was only associated with LDL-C in the CKD group (OR: 0.93, P=0.013). Based on the findings of this study, CKD and DM patients had a higher prevalence of olfactory dysfunction than the controls, which could be associated with some preventive nutritional factors. This information may help perform a screening program and early intervention on olfactory dysfunction in these systematic diseases.
- 21 March 2025
- Vol. 16 (2) , 289-296
Open AccessOdor olfactory dysfunction in chronic kidney disease and diabetes mellitus and its association with nutritional factors
Olfactory changes connection to deteriorated quality of life in chronic kidney disease cases (CKD) and diabetes mellitus (DM). The nutritional status is altered in CKD and DM and it closely interconnected with olfactory function. We aimed to study the olfactory dysfunction in these populations. We conducted a cross-sectional research on CKD and DM cases aged 20-50 (27 healthy controls, 77 CKD patients, and 36 DM patients). We used the Iran Smell Identification Test (Iran-SIT) version of the University of Pennsylvania Smell Identification Test (UPSIT) to evaluate the olfactory function. The significant level was set as <0.05. Our 140 cases included 51.4% of men (mean age of 46.7±10.6 years). The total score of the Iran-SIT test indicated that olfactory impairment in the CKD was higher (16.2±4.2) than in the DM (18.8±2.1) and control groups (20.4±1.2) (P=0.001). It was determined that 54.5% of CKD patients and 38.9% of the DM group had olfactory dysfunction compared to 7.4% of the controls (P=0.001). Multiple regression analysis indicated that being men and low-density lipoprotein cholesterol (LDL-C) were related to olfactory dysfunction in the total population (OR: 4.55, P=0.037, and OR: 0.94, P=0.037). Still, it was only associated with LDL-C in the CKD group (OR: 0.93, P=0.013). Based on the findings of this study, CKD and DM patients had a higher prevalence of olfactory dysfunction than the controls, which could be associated with some preventive nutritional factors. This information may help perform a screening program and early intervention on olfactory dysfunction in these systematic diseases.
- 1 October 2024
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 22 (10) , 760-766
Investigating Factors Influencing Kidney Transplant Decisions in Patients on Chronic Hemodialysis: A Study at Shiraz University of Medical Sciences
Objectives: End-stage renal disease is a health concern around the world. Kidney transplant substantially improves survival compared with dialysis. Although kidney transplant is the better choice for treatment of end-stage renal disease, most patient refuse this option. In this study, we aimed to find the most common reasons why patients did not undergo a kidney transplant. Materials and Methods: We conducted a cross-sectional study involving 263 patients on chronic hemodialysis in hemodialysis centers in Shiraz, Iran, in 2024. We collected data via structured interviews, which had questions on demographics, disease characteristics, dialysis details, and reasons for transplant refusal. P < .05 was considered significant. Results: In our study cohort, mean age was 60.2 +/- 16.8 years and 57.8% were male patients. The most prevalent reason for refusing kidney transplant was patient-centric barriers for kidney transplant (47.7%); difficulties with the transplant process included financial concern (33.7%), unacceptability of outcomes (30.2%), and worries about the unpredictability of transplant outcome (24.1%). The mean age of patients on the kidney transplant waiting list was 51.7 +/- 16.4 years, and mean age of those who declined a kidney transplant was 60.2 +/- 16.8 years (P < .001). Among patients on the waiting list, 68.7% were married compared with 81.7% of patients who declined a kidney transplant (P = .011). Conclusions: Addressing financial concerns by possibly improving insurance coverage, enhancing patient education on transplant benefits and risks, and providing psychological support can potentially increase acceptance rates. Tailored interventions focusing on individual patient concerns and improving communication between health care providers and patients are essential.
- 1 October 2024
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 22 (10) , 760-766
Investigating Factors Influencing Kidney Transplant Decisions in Patients on Chronic Hemodialysis: A Study at Shiraz University of Medical Sciences
Objectives: End-stage renal disease is a health concern around the world. Kidney transplant substantially improves survival compared with dialysis. Although kidney transplant is the better choice for treatment of end-stage renal disease, most patient refuse this option. In this study, we aimed to find the most common reasons why patients did not undergo a kidney transplant. Materials and Methods: We conducted a cross-sectional study involving 263 patients on chronic hemodialysis in hemodialysis centers in Shiraz, Iran, in 2024. We collected data via structured interviews, which had questions on demographics, disease characteristics, dialysis details, and reasons for transplant refusal. P < .05 was considered significant. Results: In our study cohort, mean age was 60.2 +/- 16.8 years and 57.8% were male patients. The most prevalent reason for refusing kidney transplant was patient-centric barriers for kidney transplant (47.7%); difficulties with the transplant process included financial concern (33.7%), unacceptability of outcomes (30.2%), and worries about the unpredictability of transplant outcome (24.1%). The mean age of patients on the kidney transplant waiting list was 51.7 +/- 16.4 years, and mean age of those who declined a kidney transplant was 60.2 +/- 16.8 years (P < .001). Among patients on the waiting list, 68.7% were married compared with 81.7% of patients who declined a kidney transplant (P = .011). Conclusions: Addressing financial concerns by possibly improving insurance coverage, enhancing patient education on transplant benefits and risks, and providing psychological support can potentially increase acceptance rates. Tailored interventions focusing on individual patient concerns and improving communication between health care providers and patients are essential.
- Open Access
- 1 September 2024
- Vol. 15 (4) , 606-614
Immunohistochemical markers in predicting behavior of bladder urothelial carcinoma
Background: Bladder cancer is the 5 th most prevalent cancer among Iranian men. Finding prognostic markers to predict behavior of this cancer can help us to choose the best treatment for patients from the first place. We aimed to evaluate the correlation of immunohistochemical markers with tumor stage, grade and prognosis of disease. Methods: In this study, we reassessed the specs of proven UC among Iranian patients. Sixty specimens were collected, contained of 30 low grade and 30 high grade urothelial carcinomas. All slides were assessed by immunohistochemistry study for p21, p27, Her-2/neu, E-cadherin, and CD10. Data were analyzed by SPSS 18.0 and a p-value < 0.05 was considered significant. Results: We evaluated 60 patients in this study with mean age of 66 +/- 11 years and majority of them are men. High expression of p27 showed significant correlation with LGUC (P=0.030). HGUC related with high expression of Her-2/neu, CD10 and aberrant expression of E-Cadherin (P<0.0001). Aberrant E-Cadherin and high expression of CD10 are associated with higher tumor stage (P=0.000). CD10 intensity was the only immunohistochemical markers to predict prognosis (P=0.010). Conclusion: In the present study, CD10 intensity is the only marker that directly predicts the prognosis. The higher intensity leads to poor prognosis (recurrence or metastasis). More studies must be done in this aspect to resolve the controversies and clarify the role of immunohistochemical markers in predicting BC behaviors.
- 1 September 2024
- Vol. 15 (4) , 606-614
Open AccessImmunohistochemical markers in predicting behavior of bladder urothelial carcinoma
Background: Bladder cancer is the 5 th most prevalent cancer among Iranian men. Finding prognostic markers to predict behavior of this cancer can help us to choose the best treatment for patients from the first place. We aimed to evaluate the correlation of immunohistochemical markers with tumor stage, grade and prognosis of disease. Methods: In this study, we reassessed the specs of proven UC among Iranian patients. Sixty specimens were collected, contained of 30 low grade and 30 high grade urothelial carcinomas. All slides were assessed by immunohistochemistry study for p21, p27, Her-2/neu, E-cadherin, and CD10. Data were analyzed by SPSS 18.0 and a p-value < 0.05 was considered significant. Results: We evaluated 60 patients in this study with mean age of 66 +/- 11 years and majority of them are men. High expression of p27 showed significant correlation with LGUC (P=0.030). HGUC related with high expression of Her-2/neu, CD10 and aberrant expression of E-Cadherin (P<0.0001). Aberrant E-Cadherin and high expression of CD10 are associated with higher tumor stage (P=0.000). CD10 intensity was the only immunohistochemical markers to predict prognosis (P=0.010). Conclusion: In the present study, CD10 intensity is the only marker that directly predicts the prognosis. The higher intensity leads to poor prognosis (recurrence or metastasis). More studies must be done in this aspect to resolve the controversies and clarify the role of immunohistochemical markers in predicting BC behaviors.
- Open Access
- 30 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
The effectiveness of curcumin as a safe agent on hearing threshold improvement in patients with chronic kidney disease: a double-blind, placebo-controlled trial
Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III–V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.
- 30 July 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Open AccessThe effectiveness of curcumin as a safe agent on hearing threshold improvement in patients with chronic kidney disease: a double-blind, placebo-controlled trial
Hearing impairment in patients with chronic kidney disease (CKD), can affect the quality of life. At present, hearing dysfunction does not have an approved pharmacologic therapy. This study aimed to investigate the protective effects and possible mechanisms of curcumin as a therapeutic agent on hearing impairment in patients with chronic kidney disease. We conducted a randomized controlled trial of 40 chronic kidney disease patients not on dialysis with hearing impairment. Participants were randomly divided into two groups. One group received curcumin daily and the other received a placebo for 12 weeks. The interval between III and V waves, latency of wave V, auditory brain stem response (ABR) threshold, speech reception threshold (SRT), and speech discrimination score (SDS) were evaluated and analyzed before and after the intervention. After treatment, in the curcumin group, III–V waves interval and the latency of wave V were significantly reduced (P value < 0.0001), also ABR threshold was demonstrated a significant improvement (P value < 0.0001). In the trial group, the SDS was increased (P = 0.001) and the SRT was attenuated (P < 0.0001). We had either significant deterioration due to the course of the disease or insignificant changes in the placebo group. Daily administration of curcumin, can significantly improve hearing impairment in CKD patients. Accordingly, curcumin should be considered as a therapeutic option for treating hearing impairment in patients with chronic kidney disease.
- Open Access
- 17 April 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001319
Management of hepatorenal syndrome and associated outcomes: a systematic review
Background Hepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS. Methods The authors searched PubMed, Scopus and Google Scholar literature. After quality assessment, 31 studies were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology and the population, intervention, comparison and outcome scheme were used. We included human-controlled trials that evaluate the current treatment for HRS. Two authors independently screened articles for inclusion, extracted data and assessed the quality of included studies. Results This study investigated the studies conducted on the effects of different treatments on follow-up of HRS patients. We gathered 440 articles, so 31 articles remained in our study. Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an insignificant lower rate of the model for end-stage liver disease score for terlipressin, 15 studies showed a decreased mortality rate in the terlipressin group (4 of them were significant). Conclusion This review showed that terlipressin has a significantly higher reversal rate of HRS than the other treatments. Even the results showed that terlipressin is more efficient than midodrine/octreotide and norepinephrine as a previous medication, in reverse HRS, increasing patient survival.
- 17 April 2024
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 11 (1) , e001319
Open AccessManagement of hepatorenal syndrome and associated outcomes: a systematic review
Background Hepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS. Methods The authors searched PubMed, Scopus and Google Scholar literature. After quality assessment, 31 studies were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology and the population, intervention, comparison and outcome scheme were used. We included human-controlled trials that evaluate the current treatment for HRS. Two authors independently screened articles for inclusion, extracted data and assessed the quality of included studies. Results This study investigated the studies conducted on the effects of different treatments on follow-up of HRS patients. We gathered 440 articles, so 31 articles remained in our study. Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an insignificant lower rate of the model for end-stage liver disease score for terlipressin, 15 studies showed a decreased mortality rate in the terlipressin group (4 of them were significant). Conclusion This review showed that terlipressin has a significantly higher reversal rate of HRS than the other treatments. Even the results showed that terlipressin is more efficient than midodrine/octreotide and norepinephrine as a previous medication, in reverse HRS, increasing patient survival.
- Open Access
- 1 January 2024
- Vol. 15 (1) , 96-100
Frequency and timing of renal biopsy complications
Background: Percutaneous renal biopsy is the primary diagnostic tool for renal diseases. In this study, we evaluated renal biopsy complications and the timing of complications.Methods: A cross-sectional study was performed on adult patients who underwent renal biopsy. The data gathering sheet collected patient characteristics. Complications were categorized as minor and major which needed an intervention. Data were analyzed using SPSS, and a p-value <0.05 was considered significant.Results: This cross-sectional study was conducted on 215 patients (mean age: 33.1 +/- 16.4 and 54.4%: women) who underwent percutaneous renal biopsy in Shiraz Nemazi Hospital for one year. Of the 298 complications that occurred, 90.2% were minors (56.1%of them microscopic hematuria). Moreover, 2 (0.7%) patients developed major complications and received a transfusion. In addition, most of the complications (98.9%, 295 ones) developed within 8 hours post-procedure. Only hemoglobin drop was significantly higher in women (41.0% vs. 21.4%, P=0.003).Conclusion: This study indicates that renal biopsy is a safe procedure; the results revealed that the significant post-biopsy complications were rare and occurred in the first 8 hours.
- 1 January 2024
- Vol. 15 (1) , 96-100
Open AccessFrequency and timing of renal biopsy complications
Background: Percutaneous renal biopsy is the primary diagnostic tool for renal diseases. In this study, we evaluated renal biopsy complications and the timing of complications.Methods: A cross-sectional study was performed on adult patients who underwent renal biopsy. The data gathering sheet collected patient characteristics. Complications were categorized as minor and major which needed an intervention. Data were analyzed using SPSS, and a p-value <0.05 was considered significant.Results: This cross-sectional study was conducted on 215 patients (mean age: 33.1 +/- 16.4 and 54.4%: women) who underwent percutaneous renal biopsy in Shiraz Nemazi Hospital for one year. Of the 298 complications that occurred, 90.2% were minors (56.1%of them microscopic hematuria). Moreover, 2 (0.7%) patients developed major complications and received a transfusion. In addition, most of the complications (98.9%, 295 ones) developed within 8 hours post-procedure. Only hemoglobin drop was significantly higher in women (41.0% vs. 21.4%, P=0.003).Conclusion: This study indicates that renal biopsy is a safe procedure; the results revealed that the significant post-biopsy complications were rare and occurred in the first 8 hours.
- 1 October 2023
- Published by Baskent University
- Vol. 21 (10) , 814-819
Comparative Study of Intravenous Immunoglobulin and Leflunomide Combination Therapy With Intravenous Immunoglobulin Single Therapy in Kidney Transplant Patients With BK Virus Infection: Single-Center Clinical Trial
Objectives: Nephropathy due to BK virus infection is a major cause of graft dysfunction and loss. No specific treatment has been developed for the BK virus. Here, we compared the combination of intravenous immunoglobulin and leflunomide versus intravenous immunoglobulin to treat BK virus nephropathy after renal transplant. Materials and Methods: This study was a randomized controlled clinical trial. Sixteen kidney transplant patients with BK virus infection were randomly divided into 2 groups; 1 group received intravenous immunoglobulin, and another group received leflunomide and intravenous immunoglobulin. P < .05 was considered statistically significant.Results: Results of a polymerase chain reaction test for BK virus after 2 months of treatment were negative in 3 patients in the intravenous immunoglobulin group and in 7 patients in the intravenous immunoglobulin + leflunomide group. The amount of BK virus decreased significantly in each group, and a significant difference was observed between the 2 groups after 3 months (P = .014). The average level of creatinine in the intravenous immunoglobulin group at 1, 2, and 3 months after treatment was 1.7 +/- 0.23, 1.8 +/- 0.5, and 1.5 +/- 0.3, respectively, and in the intravenous immunoglobulin + leflunomide group was 2.1 +/- 0.75, 1.76 +/- 0.37, and 1.4 +/- 0.18, respectively (P > .05).Conclusions: Although BK viral load decreased significantly in both groups, there was a significant difference between patients who received intravenous immunoglobulin versus those who received the combination of intravenous immunoglobulin + leflunomide after 3 months. The addition of leflunomide to the intravenous immunoglobulin treatment seems to have a better effect in reducing BK viral load. However, further studies with a larger sample and longer duration are needed.
- 1 October 2023
- Published by Baskent University
- Vol. 21 (10) , 814-819
Comparative Study of Intravenous Immunoglobulin and Leflunomide Combination Therapy With Intravenous Immunoglobulin Single Therapy in Kidney Transplant Patients With BK Virus Infection: Single-Center Clinical Trial
Objectives: Nephropathy due to BK virus infection is a major cause of graft dysfunction and loss. No specific treatment has been developed for the BK virus. Here, we compared the combination of intravenous immunoglobulin and leflunomide versus intravenous immunoglobulin to treat BK virus nephropathy after renal transplant. Materials and Methods: This study was a randomized controlled clinical trial. Sixteen kidney transplant patients with BK virus infection were randomly divided into 2 groups; 1 group received intravenous immunoglobulin, and another group received leflunomide and intravenous immunoglobulin. P < .05 was considered statistically significant.Results: Results of a polymerase chain reaction test for BK virus after 2 months of treatment were negative in 3 patients in the intravenous immunoglobulin group and in 7 patients in the intravenous immunoglobulin + leflunomide group. The amount of BK virus decreased significantly in each group, and a significant difference was observed between the 2 groups after 3 months (P = .014). The average level of creatinine in the intravenous immunoglobulin group at 1, 2, and 3 months after treatment was 1.7 +/- 0.23, 1.8 +/- 0.5, and 1.5 +/- 0.3, respectively, and in the intravenous immunoglobulin + leflunomide group was 2.1 +/- 0.75, 1.76 +/- 0.37, and 1.4 +/- 0.18, respectively (P > .05).Conclusions: Although BK viral load decreased significantly in both groups, there was a significant difference between patients who received intravenous immunoglobulin versus those who received the combination of intravenous immunoglobulin + leflunomide after 3 months. The addition of leflunomide to the intravenous immunoglobulin treatment seems to have a better effect in reducing BK viral load. However, further studies with a larger sample and longer duration are needed.